A retatrutide ELISA kit can turn a rack of plasma samples into a concentration–time curve in an afternoon — but only if the assay has been qualified in your own matrix and species. This guide covers how to select drug-specific ELISA kits for retatrutide, tirzepatide, semaglutide, and related incretin analogs in preclinical pharmacokinetic (PK) studies, what to qualify before reporting a number, and when to bridge to LC-MS/MS instead.
Why Your Retatrutide PK Curve Depends on Assay Specificity
You are running a rodent or non-human primate study on an incretin analog, and you need plasma concentration–time data to fit a PK model. LC-MS/MS is the reference method, but it requires instrument time, a dedicated method, and internal standards you may not have. An immunoassay gives you a 96-well plate and a colorimetric readout in an afternoon.
The catch is specificity. Retatrutide, tirzepatide, semaglutide, dulaglutide, and liraglutide are all fatty acid–modified peptides built on a related incretin backbone. An antibody raised against one may recognize others, and it may also recognize endogenous GLP-1 or GIP in your matrix. If your study design involves a comparator arm, a switch, or an animal model with meaningful endogenous incretin tone, an assay you have not characterized will return numbers that look clean and mean something other than what you think.
This note walks through how to set up a peptide drug ELISA so the concentrations you report survive scrutiny — and where to stop and run an orthogonal method instead.
Retatrutide Half-Life, Albumin Binding, and What They Mean for Your Assay
Retatrutide (LY3437943) is a single fatty diacid–conjugated peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. In vitro it shows relatively balanced glucagon and GLP-1 receptor activity with greater potency at the GIP receptor (Coskun et al., Cell Metab 2022). The retatrutide half-life is approximately six days with dose-proportional pharmacokinetics, which supports once-weekly subcutaneous dosing (Urva et al., Lancet 2022).
Three features make lipidated incretin peptides demanding to measure:
- Drug-specific detection is required. Retatrutide shares design features with other incretin-based agents, so a generic GLP-1 immunoassay will not give you drug concentration. PK kits solve this with antibody pairs raised against the specific drug, which is why each analog has its own dedicated kit rather than a shared one.
- Lipidation and protein binding. The fatty diacid moiety drives albumin binding, which extends half-life but also means a fraction of your analyte is complexed in plasma. Sample handling and dilution buffer can shift the free/bound equilibrium and therefore the apparent concentration.
- Long half-life, wide dynamic range. A six-day half-life over a multi-week study means samples span a large concentration range. A single dilution factor will not keep every timepoint on the linear part of the curve.
Clinical PK is well characterized across phase 1b, phase 2, and now phase 3 programs (Jastreboff et al., NEJM 2023; Rosenstock et al., Lancet 2023; Sanyal et al., Nat Med 2024). Preclinical and translational work in independent labs is where assay-level decisions still sit with the investigator.
How to Qualify a Retatrutide ELISA Kit: Five Checks Before You Report
1. Confirm the standard curve range fits your study, not the other way around
The BioHippo Retatrutide ELISA Kit reports a quantitative range of 78.125–5,000 ng/mL with an analytical sensitivity of 33.12 ng/mL in serum and plasma. Map your expected Cmax and terminal timepoints onto that range before you run anything. Late timepoints in a long-half-life study frequently fall below the LLOQ, and a value reported at the bottom of the curve is not the same as a measured value.
2. Run dilution linearity in your actual matrix
Serial-dilute a high-concentration study sample (not a spiked buffer standard) across at least four dilutions and back-calculate. Non-parallelism between your sample curve and the standard curve is the single most informative red flag in peptide bioanalysis — it usually indicates matrix interference or a binding-protein effect, and it invalidates the assumption that one dilution factor applies to all timepoints.
3. Establish spike recovery per species and per matrix
The kit specifies typical recovery of 80–120%. Confirm that in your own species and anticoagulant. Mouse plasma, rat serum, and NHP plasma are not interchangeable matrices, and EDTA, heparin, and citrate can each behave differently with a lipidated peptide. Spike at low, mid, and high points on the curve.
4. Qualify selectivity for multi-analog study designs
Drug-specific kits are built to discriminate their analyte, and for a single-agent study the analyte-matched kit is the answer. If your design puts two analogs in the same program — a comparator arm, a crossover, or a switch study — running each related peptide through each assay once at pharmacologically relevant concentrations documents selectivity for your specific pairing and takes an afternoon. It is standard method qualification, and reviewers expect to see it.
5. Bridge to an orthogonal method for anything that leaves your lab
For regulated bioanalysis, or for any dataset supporting a dose-selection or comparability claim, cross-validate a subset of samples by LC-MS/MS. ELISA is well suited to screening, exploratory PK, and relative comparisons across arms; it is not a substitute for a validated mass-spec method when the numbers carry regulatory weight.
Documentation. The product page lists sensitivity, quantitative range, and recovery. Full selectivity and interference data sits in the manufacturer's technical documentation rather than the public listing — if your protocol or your reviewers require it on file, ask us and we will request the complete datasheet from the manufacturer for you.
Troubleshooting Peptide PK ELISA Results
| What you observe | Most likely cause | What to do |
|---|---|---|
| Back-calculated concentration rises as you dilute further | Matrix interference or binding-protein sequestration at low dilution | Establish a minimum required dilution; report all samples at or above it |
| Recovery consistently below 80% | Analyte binding to albumin or to tube surfaces; adsorptive loss | Add carrier protein to diluent, use low-bind tubes, minimize freeze–thaw |
| Signal in predose or vehicle-control samples | Nonspecific matrix binding, or carryover between wells | Run a blank-matrix panel to establish your true background; check wash steps |
| High-concentration samples read lower than expected | Hook effect in a one-step format, or samples above ULOQ | Dilute into range and re-run; never report an above-curve value |
| Poor inter-plate agreement across a long study | Standard curve drift; operator or lot variation | Run a QC sample set on every plate; bridge across kit lots before switching |
| Terminal timepoints cluster near LLOQ | Long half-life outrunning the assay's lower limit | Extend sampling density earlier, or move to LC-MS/MS for the terminal phase |
Practical note. Freeze–thaw stability is the most commonly skipped experiment in peptide PK and the most commonly cited weakness afterward. Characterize at least three cycles in your own matrix before you commit a study's worth of samples to a single storage plan.
Incretin, Insulin Analog, and Peptide Hormone PK ELISA Kits
BioHippo's Pharmacokinetic ELISA Kit collection covers incretin analogs, insulin analogs, and therapeutic antibodies on a common quantitative colorimetric platform, which makes cross-analyte comparison within a study program more tractable. Kits below are 96-well, serum- and plasma-compatible, and supplied for research use only.
Incretin and metabolic peptides
| Kit | Range | Sensitivity | Format |
|---|---|---|---|
|
Retatrutide ELISA Kit GIP/GLP-1/glucagon triple agonist · LY3437943 |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Tirzepatide ELISA Kit GIP/GLP-1 dual agonist · LY3298176 |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Semaglutide ELISA Kit GLP-1 receptor agonist |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Dulaglutide ELISA Kit GLP-1-Fc fusion · LY2189265 |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Liraglutide ELISA Kit GLP-1 receptor agonist |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Orforglipron ELISA Kit Non-peptide oral GLP-1 agonist · LY3502970 |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
|
Albiglutide ELISA Kit GLP-1-albumin fusion |
78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
Insulin analogs
| Kit | Range | Sensitivity | Format |
|---|---|---|---|
| Insulin Glargine ELISA Kit | 78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
| Insulin Degludec ELISA Kit | 78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
| Insulin Lispro ELISA Kit | 78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
| Insulin Aspart ELISA Kit | 78.125–5,000 ng/mL | 33.12 ng/mL | 96 T |
Peptide hormones
| Kit | Range | Assay | Format |
|---|---|---|---|
|
Human Growth Hormone (Somatropin) PK ELISA hGH / GH1 |
9.375–500 ng/mL | Sandwich, ~2.5 h | 96 wells |
|
Teriparatide ELISA Kit PTH 1-34 analog |
78.125–5,000 ng/mL | Quantitative colorimetric | 96 T |
Therapeutic antibody PK kits (etanercept, ustekinumab, cetuximab, evolocumab, denosumab and others) sit in the Biologic Drug PK Monitoring collection, with the wider set under Therapeutic Drug Monitoring.
Catalog gaps — stated up front. Two things researchers ask for that we do not currently stock:
Anti-drug antibody (ADA) assays. The kits above measure drug concentration, not immunogenicity. A bridging ADA assay is a separate reagent set and is not currently in the BioHippo catalog for these analytes. If your protocol includes an immunogenicity endpoint, plan for a second sourcing path.
Several incretin analogs have no matched PK kit. Exenatide and pramlintide are available as recombinant peptides for use as standards or in functional assays, but not as PK ELISA kits. Cagrilintide, survodutide, and mazdutide are not currently represented in either form.
FAQ: Peptide Drug Quantification by ELISA
Can I use a retatrutide ELISA kit to measure tirzepatide or semaglutide?
Use the analyte-matched kit. These are drug-specific assays — each analog has its own antibody pair and its own SKU precisely because the kits are built to detect one drug rather than the class. A retatrutide kit is designed to measure retatrutide, and BioHippo stocks dedicated kits for tirzepatide, semaglutide, dulaglutide, liraglutide, and orforglipron alongside it. If a single study spans more than one analog, document selectivity for that specific pairing as part of your method qualification.
ELISA or LC-MS/MS for preclinical incretin PK?
ELISA is the practical choice for exploratory PK, dose-ranging, relative comparisons between arms, and any situation where throughput matters more than absolute accuracy. LC-MS/MS is the right call when you need unambiguous specificity against structurally related compounds, when the data supports a regulatory submission, or when you are working below the immunoassay's LLOQ. Many programs use both: ELISA for the bulk of samples, mass spec to cross-validate a subset.
Does albumin binding interfere with the measurement?
It can. Fatty acid–modified peptides bind albumin extensively, and an immunoassay measures whatever fraction the antibody can access under the assay's conditions. Dilution into assay buffer shifts that equilibrium, which is one reason dilution linearity in your own matrix is more informative than a spiked-buffer recovery experiment. Report your minimum required dilution alongside your concentrations so results are interpretable.
Will endogenous GLP-1 or GIP show up in my baseline samples?
It is unlikely to be a practical problem. Endogenous incretins circulate in the low pg/mL range while these assays operate in ng/mL, roughly three orders of magnitude apart, and the antibody pairs are raised against the drug rather than the native hormone. Including predose and vehicle-control wells is still worth doing — it establishes your true assay background for that species and matrix, which you will want when interpreting terminal timepoints near the LLOQ.
Can these kits be used on human clinical samples?
These are research use only products. They are not validated or intended for diagnostic use, clinical decision-making, therapeutic drug monitoring in patients, or verification of material obtained outside a licensed supply chain. Use in a clinical study requires the appropriate regulatory framework and, in most cases, a validated method rather than an RUO kit.
How many plates should I budget for a rodent PK study?
Work backwards from your sampling schedule. A 96-well plate accommodates roughly 36–40 samples in duplicate once you allow for a standard curve and QC wells. With a six-day half-life you will want dense early sampling plus a long terminal tail, so multiply your animal count by timepoints and add 20–30% for reruns and dilution repeats. Order enough kit lots at once to avoid a lot change mid-study, or plan a bridging experiment if you cannot.
Scope the Right Assay for Your PK Study
Tell a BioHippo technical specialist your analyte, species, matrix, and expected concentration range, and we will confirm the right kit, the documentation you will need on file, and what to qualify before you commit study samples. If your analyte is not in the catalog yet, we will tell you what we can source. Talk to a specialist →
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013 · PMID 35985340
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5 · PMID 36354040
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 · PMID 37366315
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X · PMID 37385280
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi:10.1038/s41591-024-03018-2 · PMID 38858523
For Research Use Only. Not for diagnostic or therapeutic use. The kits described are supplied for laboratory research. They are not intended for clinical diagnosis, patient management, therapeutic drug monitoring in patients, or the assessment of any material intended for human administration. Retatrutide is an investigational compound and is not approved for therapeutic use in any jurisdiction. Assay specifications are reproduced from the current manufacturer datasheets and were verified against the live BioHippo catalog at time of writing; confirm range, sensitivity, sample compatibility, and intended-use statements on each product page before purchase. Method guidance reflects general bioanalytical practice and does not replace study-specific method validation.
